TABLE 3.
miRNAs target m6A writers 3′UTR
| miRNA | Cancer type | M6A regulators | Writers' role | Validation approach/model | Function of writers | Ref |
|---|---|---|---|---|---|---|
| miR‐33a | NSCLC | METTL3 | Oncogene | Dual luciferase report assay (cell) | Stimulate EGFR pathway | 62 |
| miR‐338‐5p | NSCLC | METTL3 | Oncogene | Dual luciferase report assay (cell) | Enhance c‐MYC m6A level and expression | 63 |
| miR‐186 | Hepatoblastoma | METTL3 | Oncogene | Dual luciferase report assay, miRNA mimic/inhibitor (cell, mouse) | Stimulate Wnt/β‐catenin pathway | 64 |
| miR‐4429 | Gastric cancer | METTL3 | Oncogene | Dual luciferase report assay, miRNA mimic/inhibitor (cell) | Increase SEC62 expression and disturb ER apoptosis pathway | 65 |
| let‐7g | Breast cancer | METTL3 | Oncogene | Dual luciferase report assay, miRNA mimic/inhibitor (cell) | Promote proliferation and inhibit apoptosis | 86 |
| miR‐600 | LUAC | METTL3 | Oncogene | Dual luciferase report assay, miRNA mimic/inhibitor (cell) | Stimulate PI3K/AKT/Bcl2 to disturb mitochondrial apoptosis | 66 |
| miR‐4443 | NSCLC | METTL3 | Suppress | Dual luciferase report assay, miRNA mimic/inhibitor (cell) | Inhibit ferroptosis‐related FSP1 to suppress ferroptosis and impair cisplatin efficacy | 67 |
| miR‐193b‐5p | Gastric cancer | METTL3 | Oncogene | Dual luciferase report assay, miRNA mimic/inhibitor (cell) | Promote gastric cancer progression | 87 |
| miR‐186 | Oesophageal cancer | METTL3 | Oncogene | Dual luciferase report assay, miRNA mimic/inhibitor (cell) | Alter m6A level globally, promote proliferation and inhibit apoptosis | 88 |
| miR‐139‐5p | HCC | WTAP | Oncogene | Dual luciferase report assay, miRNA mimic/inhibitor (cell) | Promote EMT | 68 |
Abbreviations: EMT, epithelial‐mesenchymal transition; HCC, hepatocellular cancer; LUAC, lung adenocarcinoma; NSCLC, non‐small cell lung cancer.